These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 34447793)

  • 1. Iron Deficiency: A New Target for Patients With Heart Failure.
    Rizzo C; Carbonara R; Ruggieri R; Passantino A; Scrutinio D
    Front Cardiovasc Med; 2021; 8():709872. PubMed ID: 34447793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale and design of the AFFIRM-AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure.
    Ponikowski P; Kirwan BA; Anker SD; Dorobantu M; Drozdz J; Fabien V; Filippatos G; Haboubi T; Keren A; Khintibidze I; Kragten H; Martinez FA; McDonagh T; Metra M; Milicic D; Nicolau JC; Ohlsson M; Parhomenko A; Pascual-Figal DA; Ruschitzka F; Sim D; Skouri H; van der Meer P; Jankowska EA
    Eur J Heart Fail; 2019 Dec; 21(12):1651-1658. PubMed ID: 31883356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association Between Hemoglobin Levels and Efficacy of Intravenous Ferric Carboxymaltose in Patients With Acute Heart Failure and Iron Deficiency: An AFFIRM-AHF Subgroup Analysis.
    Filippatos G; Ponikowski P; Farmakis D; Anker SD; Butler J; Fabien V; Kirwan BA; Macdougall IC; Metra M; Rosano G; Ruschitzka F; van der Meer P; Wächter S; Jankowska EA;
    Circulation; 2023 May; 147(22):1640-1653. PubMed ID: 37051919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency.
    van Veldhuisen DJ; Ponikowski P; van der Meer P; Metra M; Böhm M; Doletsky A; Voors AA; Macdougall IC; Anker SD; Roubert B; Zakin L; Cohen-Solal A;
    Circulation; 2017 Oct; 136(15):1374-1383. PubMed ID: 28701470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous iron supplementation improves energy metabolism of exercising skeletal muscles without effect on either oxidative stress or inflammation in male patients with heart failure with reduced ejection fraction.
    Drozd MD; Tkaczyszyn M; Kasztura M; Węgrzynowska-Teodorczyk K; Flinta I; Banasiak W; Ponikowski P; Jankowska EA
    Cardiol J; 2024; 31(2):300-308. PubMed ID: 37853824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationale and design of the CONFIRM-HF study: a double-blind, randomized, placebo-controlled study to assess the effects of intravenous ferric carboxymaltose on functional capacity in patients with chronic heart failure and iron deficiency.
    Ponikowski P; van Veldhuisen DJ; Comin-Colet J; Ertl G; Komajda M; Mareev V; McDonagh TA; Parkhomenko A; Tavazzi L; Levesque V; Mori C; Roubert B; Filippatos G; Ruschitzka F; Anker SD
    ESC Heart Fail; 2014 Sep; 1(1):52-58. PubMed ID: 28834668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous ferric carboxymaltose for iron repletion following acute heart failure in patients with and without diabetes: a subgroup analysis of the randomized AFFIRM-AHF trial.
    Rosano G; Ponikowski P; Vitale C; Anker SD; Butler J; Fabien V; Filippatos G; Kirwan BA; Macdougall IC; Metra M; Ruschitzka F; Kumpeson V; Goehring UM; van der Meer P; Jankowska EA;
    Cardiovasc Diabetol; 2023 Aug; 22(1):215. PubMed ID: 37592272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency†.
    Ponikowski P; van Veldhuisen DJ; Comin-Colet J; Ertl G; Komajda M; Mareev V; McDonagh T; Parkhomenko A; Tavazzi L; Levesque V; Mori C; Roubert B; Filippatos G; Ruschitzka F; Anker SD;
    Eur Heart J; 2015 Mar; 36(11):657-68. PubMed ID: 25176939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Iron Deficiency, Anemia, and Iron Supplementation in Patients With Heart Failure: A Population-Level Study.
    Wahid M; Islam S; Sepehrvand N; Dover DC; McAlister FA; Kaul P; Ezekowitz JA
    Circ Heart Fail; 2024 Apr; 17(4):e011351. PubMed ID: 38572652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iron substitution in the treatment of chronic heart failure.
    Gstrein C; Meyer M; Anabitarte P
    Swiss Med Wkly; 2017; 147():w14453. PubMed ID: 28695549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of ischaemic aetiology on the efficacy of intravenous ferric carboxymaltose in patients with iron deficiency and acute heart failure: insights from the AFFIRM-AHF trial.
    Metra M; Jankowska EA; Pagnesi M; Anker SD; Butler J; Dorigotti F; Fabien V; Filippatos G; Kirwan BA; Macdougall IC; Rosano G; Ruschitzka F; Tomasoni D; van der Meer P; Ponikowski P;
    Eur J Heart Fail; 2022 Oct; 24(10):1928-1939. PubMed ID: 35869741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Ferric Carboxymaltose Supplementation in Patients with Heart Failure with Preserved Ejection Fraction: Role of Attenuated Oxidative Stress and Improved Endothelial Function.
    Mollace A; Macrì R; Mollace R; Tavernese A; Gliozzi M; Musolino V; Carresi C; Maiuolo J; Nicita M; Caminiti R; Paone S; Barillà F; Volterrani M; Mollace V
    Nutrients; 2022 Nov; 14(23):. PubMed ID: 36501086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis.
    Anker SD; Kirwan BA; van Veldhuisen DJ; Filippatos G; Comin-Colet J; Ruschitzka F; Lüscher TF; Arutyunov GP; Motro M; Mori C; Roubert B; Pocock SJ; Ponikowski P
    Eur J Heart Fail; 2018 Jan; 20(1):125-133. PubMed ID: 28436136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Responder analysis for improvement in 6-min walk test with ferric carboxymaltose in patients with heart failure with reduced ejection fraction and iron deficiency.
    Anker SD; Ponikowski P; Khan MS; Friede T; Jankowska EA; Fabien V; Goehring UM; Metra M; Piña IL; Coats AJS; Rosano G; Dorigotti F; Comin-Colet J; Van Veldhuisen DJ; Filippatos GS; Butler J
    Eur J Heart Fail; 2022 May; 24(5):833-842. PubMed ID: 35334136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of intravenous ferric carboxymaltose on heart failure with preserved and reduced ejection fraction.
    López-Vilella R; Lozano-Edo S; Arenas Martín P; Jover-Pastor P; Ezzitouny M; Sorolla Romero J; Calvo Asensio M; Martínez-Solé J; Guerrero Cervera B; Sánchez Martínez JC; Donoso Trenado V; Sánchez-Lázaro I; Martinez Dolz L; Almenar Bonet L
    ESC Heart Fail; 2022 Feb; 9(1):133-145. PubMed ID: 34964300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of ferric carboxymaltose for iron deficiency at discharge after heart failure hospitalization: a European multinational economic evaluation.
    McEwan P; Harrison C; Binnie R; Lewis RD; Cohen-Solal A; Lund LH; Ohlsson M; von Haehling S; Comin-Colet J; Pascual-Figal DA; Wächter S; Dorigotti F; de Arellano AR; Ponikowski P; Jankowska EA
    Eur J Heart Fail; 2023 Mar; 25(3):389-398. PubMed ID: 36718652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anaemia, iron deficiency and heart failure in 2020: facts and numbers.
    Chopra VK; Anker SD
    ESC Heart Fail; 2020 Oct; 7(5):2007-2011. PubMed ID: 32602663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of intravenous iron replacement on recurrent heart failure hospitalizations and cardiovascular mortality in patients with heart failure and iron deficiency: A Bayesian meta-analysis.
    Anker SD; Khan MS; Butler J; von Haehling S; Jankowska EA; Ponikowski P; Friede T
    Eur J Heart Fail; 2023 Jul; 25(7):1080-1090. PubMed ID: 37062867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identifying responders to oral iron supplementation in heart failure with a reduced ejection fraction: a post-hoc analysis of the IRONOUT-HF trial.
    Ambrosy AP; Lewis GD; Malhotra R; Jones AD; Greene SJ; Fudim M; Coles A; Butler J; Sharma A; Hernandez AF; Mentz RJ
    J Cardiovasc Med (Hagerstown); 2019 Apr; 20(4):223-225. PubMed ID: 30540649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TIDILAP: Treatment of iron deficiency in lipoprotein apheresis patients --A prospective observational multi-center cohort study comparing efficacy, safety and tolerability of ferric gluconate with ferric carboxymaltose.
    Schatz U; Illigens BM; Siepmann T; Arneth B; Siegert G; Siegels D; Heigl F; Hettich R; Ramlow W; Prophet H; Bornstein SR; Julius U
    Atheroscler Suppl; 2015 May; 18():199-208. PubMed ID: 25936327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.